Ironwood Pharmaceuticals Inc last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $133.0 million (+9.0% year over year) and diluted EPS of $0.36. It usually reports 2–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 1, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Friday. Based on last year's release for the same quarter on Jan 2, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 2–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
133
+9.0%
|
60
+49.3%
|
0.36
+56.5%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
113
+32.6%
|
51
+117.3%
|
0.31
+121.4%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
107
+158.9%
|
41
+209.1%
|
0.24
+204.3%
|
|
Jan 2, 2026
2 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
48
-47.3%
|
-2
-200.9%
|
-0.01
-200.0%
|
|
Nov 10, 2025
41 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
122
+33.3%
|
40
+999.3%
|
0.23
+1050.0%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
85
-9.7%
|
24
+2844.1%
|
0.14
+1500.0%
|
|
Apr 25, 2025
25 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
41
-45.1%
|
-37
-798.3%
|
-0.23
-666.7%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
91
-23.0%
|
2
+307.5%
|
0.01
+200.0%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IRWD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1446847
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.